Editorial: Bivalirudin versus unfractionated heparin in acute myocardial infarction: Why are we still debating?

Cardiovasc Revasc Med. 2024 Apr:61:62-63. doi: 10.1016/j.carrev.2023.11.008. Epub 2023 Nov 11.

Authors

Marc Cohen¹, Sumit Sohal²

Affiliations

¹ Section of Cardiovascular Medicine, Department of Internal Medicine, Newark Beth Israel Medical Center, Newark, NJ 07112, United States of America. Electronic address: marc.cohen@rwjbh.org.
² Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States of America.

PMID: 37980264
DOI: 10.1016/j.carrev.2023.11.008

No abstract available

Publication types

Editorial

MeSH terms

Heparin* / adverse effects
Hirudins / adverse effects
Humans
Myocardial Infarction* / drug therapy
Peptide Fragments / therapeutic use
Recombinant Proteins

Substances

Heparin
bivalirudin
Hirudins
Peptide Fragments
Recombinant Proteins